JP2020517696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517696A5 JP2020517696A5 JP2019558369A JP2019558369A JP2020517696A5 JP 2020517696 A5 JP2020517696 A5 JP 2020517696A5 JP 2019558369 A JP2019558369 A JP 2019558369A JP 2019558369 A JP2019558369 A JP 2019558369A JP 2020517696 A5 JP2020517696 A5 JP 2020517696A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- months
- cancer
- her2 antibody
- adverse events
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 73
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 35
- 230000002411 adverse Effects 0.000 claims description 32
- 229960000575 trastuzumab Drugs 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 15
- 230000002503 metabolic effect Effects 0.000 claims description 15
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 12
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 229960004117 capecitabine Drugs 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 229960002087 pertuzumab Drugs 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000004083 survival effect Effects 0.000 claims description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- 229960003261 carmofur Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 229950003135 margetuximab Drugs 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 229960001674 tegafur Drugs 0.000 claims description 4
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- -1 Dokishi off Rurijin Chemical compound 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100039788 GTPase NRas Human genes 0.000 claims description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038111 Recurrent cancer Diseases 0.000 claims description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 238000011272 standard treatment Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 12
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 229940100197 antimetabolite Drugs 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 238000002203 pretreatment Methods 0.000 claims 2
- KIZQNNOULOCVDM-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].C[N+](C)(C)CCO KIZQNNOULOCVDM-UHFFFAOYSA-M 0.000 claims 1
- 206010019851 Hepatotoxicity Diseases 0.000 claims 1
- 230000007686 hepatotoxicity Effects 0.000 claims 1
- 231100000304 hepatotoxicity Toxicity 0.000 claims 1
- 229960005558 mertansine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 62
- 238000002648 combination therapy Methods 0.000 description 10
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126666A JP2023145689A (ja) | 2017-04-28 | 2023-08-03 | Ｈｅｒ２陽性がんの処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491872P | 2017-04-28 | 2017-04-28 | |
| US62/491,872 | 2017-04-28 | ||
| PCT/US2018/029899 WO2018201016A1 (en) | 2017-04-28 | 2018-04-27 | Treatment of her2 positive cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126666A Division JP2023145689A (ja) | 2017-04-28 | 2023-08-03 | Ｈｅｒ２陽性がんの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517696A JP2020517696A (ja) | 2020-06-18 |
| JP2020517696A5 true JP2020517696A5 (enExample) | 2021-09-09 |
| JP7328151B2 JP7328151B2 (ja) | 2023-08-16 |
Family
ID=62165692
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558369A Active JP7328151B2 (ja) | 2017-04-28 | 2018-04-27 | Ｈｅｒ２陽性がんの処置 |
| JP2023126666A Pending JP2023145689A (ja) | 2017-04-28 | 2023-08-03 | Ｈｅｒ２陽性がんの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126666A Pending JP2023145689A (ja) | 2017-04-28 | 2023-08-03 | Ｈｅｒ２陽性がんの処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11207324B2 (enExample) |
| EP (1) | EP3615067A1 (enExample) |
| JP (2) | JP7328151B2 (enExample) |
| KR (1) | KR102845148B1 (enExample) |
| CN (1) | CN111032082B (enExample) |
| AU (2) | AU2018258663B2 (enExample) |
| BR (1) | BR112019022280A2 (enExample) |
| CA (1) | CA3060407A1 (enExample) |
| EA (1) | EA201992573A1 (enExample) |
| MA (1) | MA49059A (enExample) |
| SG (1) | SG11201909676WA (enExample) |
| WO (1) | WO2018201016A1 (enExample) |
| ZA (1) | ZA201907225B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102845148B1 (ko) | 2017-04-28 | 2025-08-20 | 씨젠 인크. | Her2 양성 암의 치료 |
| TW202042820A (zh) * | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| AU2019450366B2 (en) * | 2019-06-11 | 2026-01-08 | Board Of Regents, The University Of Texas System | Use of an RXR agonist in treating Her2+ cancers |
| CA3156820A1 (en) * | 2019-10-21 | 2021-04-29 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab |
| AU2020381495A1 (en) * | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| WO2021243123A1 (en) * | 2020-05-29 | 2021-12-02 | Seagen Inc. | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
| CA3189333A1 (en) * | 2020-07-29 | 2022-02-03 | Seagen Inc. | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist |
| IL301405A (en) * | 2020-09-28 | 2023-05-01 | Seagen Inc | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| US11526994B1 (en) * | 2021-09-10 | 2022-12-13 | Neosoma, Inc. | Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images |
| WO2024183622A1 (zh) * | 2023-03-03 | 2024-09-12 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
| WO2025132522A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| EP1768963A4 (en) | 2004-06-03 | 2009-06-10 | Smithkline Beecham Cork Ltd | CANCER TREATMENT METHOD |
| KR101086967B1 (ko) | 2005-11-15 | 2011-11-29 | 어레이 바이오파마 인크. | 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물 |
| WO2009042618A1 (en) | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| HUE035184T2 (en) | 2008-03-18 | 2018-05-02 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| JP6468838B2 (ja) * | 2011-05-19 | 2019-02-13 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |
| JP5944514B2 (ja) | 2011-10-14 | 2016-07-05 | アレイ バイオファーマ、インコーポレイテッド | 固体分散体 |
| RU2629116C2 (ru) | 2011-10-14 | 2017-08-24 | Эррэй Биофарма Инк. | Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их |
| NZ756264A (en) | 2012-03-23 | 2022-09-30 | Array Biopharma Inc | Treatment of brain cancer |
| CA2955384C (en) * | 2014-07-17 | 2024-03-12 | Biocurity Holdings, Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017184775A1 (en) * | 2016-04-19 | 2017-10-26 | The Regents Of The University Of California | Erbb inhibitors and uses thereof |
| KR102845148B1 (ko) | 2017-04-28 | 2025-08-20 | 씨젠 인크. | Her2 양성 암의 치료 |
| WO2019241599A1 (en) | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
| TW202042820A (zh) | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| CA3156820A1 (en) | 2019-10-21 | 2021-04-29 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab |
| AU2020381495A1 (en) | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| JP2023517078A (ja) | 2020-03-11 | 2023-04-21 | シージェン インコーポレイテッド | ツカチニブを用いてｈｅｒ２突然変異を有するがんを処置する方法 |
-
2018
- 2018-04-27 KR KR1020197035001A patent/KR102845148B1/ko active Active
- 2018-04-27 CA CA3060407A patent/CA3060407A1/en active Pending
- 2018-04-27 SG SG11201909676W patent/SG11201909676WA/en unknown
- 2018-04-27 EA EA201992573A patent/EA201992573A1/ru unknown
- 2018-04-27 EP EP18724716.8A patent/EP3615067A1/en active Pending
- 2018-04-27 AU AU2018258663A patent/AU2018258663B2/en active Active
- 2018-04-27 CN CN201880043831.3A patent/CN111032082B/zh active Active
- 2018-04-27 US US16/607,850 patent/US11207324B2/en active Active
- 2018-04-27 MA MA049059A patent/MA49059A/fr unknown
- 2018-04-27 JP JP2019558369A patent/JP7328151B2/ja active Active
- 2018-04-27 WO PCT/US2018/029899 patent/WO2018201016A1/en not_active Ceased
- 2018-04-27 BR BR112019022280A patent/BR112019022280A2/pt unknown
-
2019
- 2019-10-30 ZA ZA2019/07225A patent/ZA201907225B/en unknown
-
2021
- 2021-11-18 US US17/530,265 patent/US11666572B2/en active Active
-
2022
- 2022-09-28 AU AU2022241509A patent/AU2022241509B2/en active Active
-
2023
- 2023-04-26 US US18/139,653 patent/US12048698B2/en active Active
- 2023-08-03 JP JP2023126666A patent/JP2023145689A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517696A5 (enExample) | ||
| US12435144B2 (en) | Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| JP2011511072A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| TW201922282A (zh) | Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 | |
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JPWO2020229626A5 (enExample) | ||
| TW200409768A (en) | Therapeutic use | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| Butty et al. | Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine | |
| CN112584834A (zh) | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 | |
| IL317954A (en) | Treatment of hematological malignancies with galectin-9 inhibitory antibodies | |
| KR20240046527A (ko) | 암치료를 위한 신규 경구용 약학적 조성물 | |
| WO2021088975A1 (zh) | 一种化合物用于预防或治疗移植物抗宿主病的用途 | |
| JP2019151621A (ja) | Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物 | |
| CN110680919A (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途 | |
| WO2011151372A1 (en) | Treatment of rheumatoid arthritis with masitinib | |
| JPWO2021243123A5 (enExample) | ||
| Liu et al. | P3. 18.46 Ivonescimab Plus Platinum-Doublet Chemotherapy as First-Line Therapy for Locally Advanced/Metastatic SMARCA4-Deficient NSCLC | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer |